Abstracts tagged "biologic response modifiers and rheumatoid arthritis (RA)"

Abstract Number: 458 • 2012 ACR/ARHP Annual Meeting
Better Retention RATE At 5 YEARS of ANTI-TNF Agents USED in Conjonction with Methotrexate Over Time in Patients with Rheumatoid Arthritis: REAL-Life DATA From Rhumadata Computarized Database
Denis Choquette¹, Diane Sauvageau², Boulos Haraoui² and Jean-Pierre Raynauld², ¹Rheumatology, Institut de Rhumatologie De Montréal, Montreal, QC, Canada, ²Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Anti-TNF agents have been in used in Canada for the last ten years. Although a vast body of clinical experience has been accumulated since…
Abstract Number: 1246 • 2012 ACR/ARHP Annual Meeting
Cardiovascular Risk Assessment in Rheumatoid Arthritis (RA) Patients Treated by Biologic Response Modifiers
Majed M. Khraishi¹, Rana Aslanov² and Katie Doyle¹, ¹Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, ²Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada
Background/Purpose: We aimed to assess the 10-year CV event risk in patients with RA at the baseline and 1 year after the initiation of treatment…
Abstract Number: 1332 • 2012 ACR/ARHP Annual Meeting
The Incidence of Exacerbation of Pre-Existing Interstitial Lung Disease (ILD) Is Higher in TNF Blockers Than in Non-TNF Blockers in RA
Tamao Nakashita¹, Shinji Motojima², Natsuki Fujio² and Akira Jibatake³, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa City, Japan, ²Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, ³Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose: Exacerbation of interstitial lung disease (ILD) is a problem when biologics are administrated in patients with RA, and not a few fatal cases have…
Abstract Number: 1841 • 2012 ACR/ARHP Annual Meeting
Lower Than Expected Levels of DMARD Acquisition Immediately Pre and Post Biologic Initiation in Rheumatoid Arthritis Patients
Denis Choquette¹, Oliver Thomas² and Mark Arundine², ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Roche, Toronto, ON, Canada
Background/Purpose: Reports suggest that a large proportion of patients who acquire and use biologic DMARD agents (biologics) to treat Rheumatoid Arthritis (RA) do not acquire…